The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

(2021) Tyler N. Starr et al.   SCIENCE

Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic

(2021) Lewis F. Buss et al.   SCIENCE

A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein

(2021) Cheolmin Kim et al.   Nature Communications

Antibody evasion by the P.1 strain of SARS-CoV-2

(2021) Wanwisa Dejnirattisai et al.   CELL

Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization

(2021) Pengfei Wang et al.   Cell Host & Microbe

Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil

(2021) Nuno R. Faria et al.   SCIENCE

Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge

(2021) Martin S. Winkler et al.   EBioMedicine

Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant

(2021) Dong-Kyun Ryu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021

(2021) Finlay Campbell et al.   Eurosurveillance

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

(2021) Delphine Planas et al.   NATURE

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains

(2021) Rita E. Chen et al.   NATURE

SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern

(2021) Matthew McCallum et al.   SCIENCE

How Could In Vitro Antiviral Activity Be Applied to Optimize the Dosing Regimens of Candidates for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)?

(2020) Ranran Jia et al.   CLINICAL INFECTIOUS DISEASES

Antibody biodistribution coefficients

(2013) Dhaval K. Shah et al.   mAbs